ESC Congress 2025
Give LDL-C lowering drugs soon after MI, advise updated guidelines
A focused update of the 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) Guidelines for the Management of Dyslipidaemias recommends rapid treatment with low-density lipoprotein cholesterol (LDL-C) lowering drugs in patients following a myocardial infarction (MI). Other recommendations included estimating cardiovascular (CV) risk using…
read more »
Updated guidelines give new recommendations on bempedoic acid
A focused update of the 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) Guidelines for the Management of Dyslipidaemias gives new recommendations for the use of bempedoic acid for low-density lipoprotein cholesterol (LDL-C) lowering in patients. The updated 2025 guidelines, launched at the ESC…
read more »
VICTORION-Difference: Inclisiran effective for LDL-C in high CV risk patients
Inclisiran therapy brought more patients with hypercholesterolaemia at high or very high risk of cardiovascular (CV) events to early and sustained LDL-C goals with fewer adverse muscle symptoms than placebo when given in addition to individualised lipid-lowering treatments, showed a large, multicentre phase IV trial….
read more »
NEWTON-CABG CardioLink 5: Is evolocumab effective in graft vein disease?
Cholesterol-lowering by evolocumab did not reduce graft vein disease in patients in the two years following coronary artery bypass surgery, according to new findings. Results from the NEWTON-CABG CardioLink 5 trial were unveiled by principal investigator Professor Subodh Verma from St. Michael’s Hospital in Toronto,…
read more »
Pharmacokinetics of AZD0780 supports its broad use
A new study of the properties of the novel, oral PCSK9 inhibitor, AZD0780, suggests it could be used to “help a large majority of patients” reach LDL-C goals. An international team of researchers presented data on the oral, small molecule PCSK9 inhibitor in a moderated…
read more »
‘Real-world’ clinical effects of inclisiran meet trial expectations
The largest reported analysis to date of low-density lipoprotein cholesterol (LDL-C) changes in patients given inclisiran suggests that real-world clinical effects match up to clinical trial data in patients starting with high LDL-C, according to a new report. The results from a study harnessing electronic…
read more »
